Cingulate signs agreement to market its first drug candidate

Cingulate Inc. announced Monday a big step, on the business side, toward rolling out its first drug. The Kansas City, Kansas, company (Nasdaq:CING) announced a joint commercialization agreement with Indegene. The companies will work to bring to market Cingulate ’s first drug candidate. The drug, CTx-1301, is billed as a once-daily medication to treat attention deficit/hyperactivity disorder (ADHD) — a market Cingulate estimates at $20 billion. Cingulate expects results from a Phase 3 trial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news